Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Notes Payables (2023 - 2024)

Biofrontera has reported Notes Payables over the past 2 years, most recently at $296000.0 for Q2 2024.

  • Quarterly results put Notes Payables at $296000.0 for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $296000.0 (changed N/A YoY), and the annual figure for FY2023 was $3.9 million, changed.
  • Notes Payables for Q2 2024 was $296000.0 at Biofrontera, down from $2.4 million in the prior quarter.
  • Over the last five years, Notes Payables for BFRIW hit a ceiling of $3.9 million in Q4 2023 and a floor of $296000.0 in Q2 2024.